Ocata Therapeutics — Advanced Cell Technology — Investor Presentation (July 2007)
55 slides from Ocata Therapeutics's investor presentation, Jul 2, 2007
Slide 1: Company Presentation July 2007
Company Presentation July 2007
Slide 2: Legal Notice: Cautionary Statement Concerning Forward-Looking Statements
This presentation contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular a
Slide 3: Stem Cell Based Therapy
Stem Cell Based Therapy Scientists worldwide believe stem cell-based therapies have the potential to restore healthy function of diseased or damaged tissues Goal is to develop therapies that work by transplanting cells and tissues derived from stem cells into the body, using the body’s natural power
Slide 4: Company Mission
Company Mission Translating World Class Stem Cell Research into Proprietary Human Therapeutic Programs
Slide 5: Recent Events Driving Forward into the Clinic
Recent Events Driving Forward into the Clinic Acquiring Mytogen and Myoblast Program Phase II Clinical Trial for the Treatment of Chronic Heart Failure Commencing GLP Studies for RPE Program Preclinical Safety Studies for the Treatment of AMD and Retinal Degenerative Disease Commencing Preclinical S
Slide 6: Key Highlights of Mytogen Acquisition
Key Highlights of Mytogen Acquisition Target Market for Myoblast Program Chronic Heart Failure - treat scar tissue caused by heart attack Clearance from FDA to Proceed with Phase II Clinical Trials Experienced Mytogen Development Team – Together for over Ten Years Strong Intellectual Property – Myto
Slide 7: Key Highlights of Mytogen Acquisition
Key Highlights of Mytogen Acquisition Gained Clearance from FDA to Proceed with Phase II Multi-Center Clinical Trial 3 Phase I Clinical Studies Completed Dosed in 42 patients No safety concerns Strong indications of efficacy Phase lb Catheter Trial Nearly Complete No SAEs for cells, no arrhythmia co
Slide 8: Key Investment Highlights: Proprietary Human Therapeutic Programs
Key Investment Highlights ACT Proprietary Human Therapeutic Programs Myoblast Program Treatment of Heart Attack Phase II and Heart Failure RPE Program Treatment of AMD and Retinal Preclinical Degenerative Diseases Hemangioblast Treatment of Disease and Disorders Preclinical Program of the Blood and
Slide 9: Key Investment Highlights: Proprietary Enabling Technology Platforms
Key Investment Highlights ACT Proprietary Enabling Technology Platforms Blastomere Program First Proven Alternative Method for hESC Derivation ACTCellerate High Throughput Derivation and Differentiation of Program Therapeutic Cell Types GMP Manufacturing Producing GMP-Compliant, Pathogen-Free Banks
Slide 10: Key Investment Highlights: World Class Scientific Team
World Class Scientific Team Lead By: Dr. Michael West President and Chief Scientific Officer Dr. Robert Lanza VP of Research & Scientific Development Dr. Pedro Huertas Chief Development Officer Industry-Leading Intellectual Property Portfolio More than 300 patents and patent applications related to
Slide 11: ACT Therapeutics: Myoblast Program
ACT Therapeutics: Myoblast Program
Slide 12: Myoblast Stem Cell Therapy
Myoblast Stem Cell Therapy Outpatient therapy to improve cardiac function in heart failure patients Harvest muscle stem cells (Myoblasts) from patient’s thigh Expand cells using proprietary culturing process Identify and map scarred regions of the heart with 3-D imaging technique Inject cells with m
Slide 13: Myoblast Clinical Trial Summary
Myoblast Clinical Trial Summary Escalating - 30, 100, 300 and 600 MM Cells Single Dose - 300 MM Cells Escalating – 10, 30, 100 and 300 MM Cells Single Dose -300 MM Cells Dose Safe at all doses, improved symptoms and function Safety Catheter Injection 23 Patients (12 treated, 11 control) Phase 1b Cat
Slide 14: Phase Ib Catheter Trial Summary
Phase Ib Catheter Trial Summary First U.S. randomized trial of catheter-delivered muscle cells Core laboratory analysis of objective endpoints Only trial with direct injection into scar (other stem cells must be delivered to viable tissue for benefit) Catheter delivery process without any complicati
Slide 15: 3-D NOGA Mapping of Myoblast Injections
3-D NOGA Mapping of Myoblast Injections 5.7 mV 8.6 mV Injections of 600 million cells into infarct region shown in red 3 months post reveals significant improvement in viability of the heart
Slide 16: Phase Ib Clinical Trial Results: NYHA Classification
Phase Ib Clinical Trial Results 3 mos: p = 0.0009, n = 23 6 mos: p < 0.0001, n = 23 A decrease in NYHA score represents an improvement in symptoms and an increase represents a worsening NYHA Classification of Heart Failure Symptoms Baseline 3mos 6mos Baseline 3mos 6mos 2.8 2.4 1.9 2.4 1.4 2.6 1 1.5
Slide 17: Phase Ib Clinical Trial Results: Comparative Effects on NYHA
Phase Ib Clinical Trial Results Control ß-blockers* ACE Inhibitors# CRT† Myoblasts * Lombardo et al., 2006 Am J Cardiovasc Drugs 6:259-63 † McAllister et al., 2004 Ann Intern Med 141:381-90 # Sliwa et al., 2004 JACC 44:1825-30 Change in NYHA at 6mos post treatment Comparative Effects of Heart Failur
Slide 18: Phase Ib Clinical Trial Results: Minnesota Living with Heart Failure Questionnaire
Phase Ib Clinical Trial Results Minnesota Living with Heart Failure Questionnaire (MLHFQ) p = 0.017, n = 23 Baseline 6mos Baseline 6mos * Improvement in patient quality of life (QOL) scores for all patients 47 47 28 46 0 10 20 30 40 50 Myoblast Control
Slide 19: Phase Ib Clinical Trial Results: 6 Minute Walk Test
Phase Ib Clinical Trial Results Average change in distance walked in 6 minutes from 3 months to 6 months for all patients 6 Minute Walk Test 81 -9 -50 0 50 100 Feet Myoblast Control
Slide 20: Phase Ib Clinical Trial Results: Ventricular Volumes
Phase Ib Clinical Trial Results Ventrical Volumes: End Systolic and End Diastolic Diameters End Systolic Diameter at 3 and 6 mos as measured by independent echocardiography core lab for all patients p = 0.06, n = 23 Baseline 3mos 6mos Baseline 3mos 6mos End Diastolic Diameter at 3 and 6 mos as measu
Slide 21: Phase Ib Clinical Trial Results: NYHA Classification vs Baseline
Phase Ib Clinical Trial Results NYHA Classification at 6 month vs Baseline for all Patients 36% 64% 0% Control 0% 17% 83% Myoblast Worsened No Change Improved
Slide 22: Plan for Phase II Clinical Trial
Plan for Phase II Clinical Trial 160 total patients (2:1 treatment vs control) Double-blind, placebo (sham procedure) controlled Catheter delivery of cells: percutaneous Three month, six month, and 12 month follow-up Endpoints: Improvement in HF symptoms and Ventricular Volumes Primary endpoint: Imp
Slide 23: ACT Therapeutics: RPE Program
ACT Therapeutics: RPE Program
Slide 24: RPE Anatomy and Function
RPE Anatomy and Function RPE Layer Deteriorates in Patients with AMD and other Retinal Degenerative Diseases absorption of stray light barrier vitamin A metabolism and transport phagocytosis of shed photoreceptor segments some functions of RPE
Slide 25: RPE Program 2006 Milestone Achieved
RPE Program 2006 Milestone Achieved: Published Data Showing hESC- derived RPE Cells Rescue Visual Function in RCS Rats
Slide 26: RPE Rescue in the RCS Rat
RPE Rescue in the RCS Rat RPE: essential for the survival of photoreceptors in the retina; believed to play a critical role in healthy vision RCS retina at P100 with RPE-9 injection: A: low power view of retina showing extensive rescue; B: high power of outline b showing rescued photoreceptors; C: h
Slide 27: RPE Program Collaboration
RPE Program Collaboration 2007 Milestone Achieved - Preclinical Development Collaboration with Casey Eye Institute at Oregon Health & Science University Dr. Raymond Lund Leading Researcher in Retinal Degenerative Disease Dr. Peter Francis Senior Researcher and Clinician Dr. Richard Weleber Senior Cl
Slide 28: RPE Program - GLP Safety Studies
RPE Program - GLP Safety Studies 2007 Milestone Achieved – Hired MPI Research to conduct our GLP Safety Studies for the RPE Program Initial Pilot Studies Commenced initial studies to demonstrate cell survival and validation of controls Pivotal Studies Full safety and tumorigenicity studies to demons
Slide 29: ACT Therapeutics: Hemangioblast Program
ACT Therapeutics: Hemangioblast Program
Slide 30: The Hemangioblast Cell
The Hemangioblast Cell Pre-cursor to all cell types of the blood and the vascular system
Slide 31: Hemangioblast Program 2006 Milestone Achieved
Hemangioblast Program 2006 Milestone Achieved: Hemangioblast Cells Generated from Blastomere Derived hESC Lines 40X 10X
Slide 32: Hemangioblast Program 2007 Milestone Achieved
Hemangioblast Program 2007 Milestone Achieved: Published Data Showing Hemangioblast Function In Vivo in Nature Methods
Slide 33: Hemangioblast Program: Repair of Ischemic Retinal Vasculatures
Hemangioblast Program Repair of Ischemic Retinal Vasculatures Mouse Rat
Slide 34: Hemangioblast Program: Restoration of Blood Flow in Ischemic Limbs
Hemangioblast Program Restoration of Blood Flow in Ischemic Limbs (Rat)
Slide 35: Hemangioblast Program: Increase in Survival Rate in Infarcted Heart
Hemangioblast Program Increase in Survival Rate in Infacted Heart (Mouse)
Slide 36: Hemangioblast Program: Breakthrough in Scaled Manufacture
Hemangioblast Program Significant Breakthrough in Scaled Manufacture of Hemangioblasts Cells Well characterized - make all cells of the blood and vascular tissues Significant Collaborations underway to generate proof of concept data in a wide range of indications Plan to generate Hemangioblasts unde
Slide 37: ACT Therapeutics: Dermal Program
ACT Therapeutics: Dermal Program
Slide 38: Skin: Dermal Cells for Wound and Burn Repair
Skin: Dermal Cells for Wound and Burn Repair ES dermal cells possess unique healing capacities of early skin cells to heal wounds without scarring. ACTC is researching ES dermal cell technology that may someday repair skin. Large application for therapies to repair damage from burns, wounds and surg
Slide 39: ACT Technology: Blastomere Program
ACT Technology: Blastomere Program
Slide 40: Blastomere Program
Blastomere Program–Most Recognized
Slide 41: Success in Human: 2006 Milestone Achieved
Success in Human 2006 Milestone Achieved: Derivation of Human hESC Lines Published in Nature
Slide 42: First Proven Alternative Method Enables Derivation of New hESC Lines
First Proven Alternative Method Enables Derivation of New hESC Lines via Preimplantation Genetic Diagnosis (PGD) Method, Preserving Development Potential of the Embryo First Proven Alternative; Presents Solution to hESC Controversy Blastomere hESC Lines May Be Eligible for Federal Funding; Company S
Slide 43: ACT Technology: ACTCellerate Program
ACT Technology: ACTCellerate Program
Slide 44: ACTCellerate – A Sleeping Beauty
ACTCellerate – A Sleeping Beauty 2006 Milestone Achieved: Announced proprietary high throughput technology platform for discovering large number of therapeutically useful, hESC-derived cell types
Slide 45: ACTCellerate Program
ACTCellerate Program Cell Sorting Gene Expression Profile Scaling in Rollers hES Cell Line ACTCellerate Cell Lines Lines Human Embryo- Derived Cells
Slide 46: ACTCellerate Program: ACT162 Cardiac Progenitor
ACTCellerate Program ACT162 Cardiac Progenitor Cardiac Muscle ACTC MYH7 MYL4 MYH3 TNNT2 Neuronal NEF3 NEFL MEIS1 CDH2 SILV ACTCellerate Cell Lines Lines
Slide 47: ACT Technology: GMP Manufacturing Program
ACT Technology: GMP Manufacturing Program
Slide 48: GMP Manufacturing Program: Facilities Opened
CENTRIF CT03002 Microscope BSC SH-01002 BSC SH-01001 Viewing Window Sterilizer OV-05001 CENTRIF CT-03001 Unclassified Pass Thru Warming Oven IN-02001 -80 Freezer CS-04002 2-8 degree C Refrigerator CS-01001 Tri-Gas Incubator IN-03001 CO2 INCUBATOR IN-01004 (top) IN-01003 (bottom) CO2 INCUBATOR IN-010
Slide 49: GMP Manufacturing Program: Dr. Pedro Huertas Hired
GMP Manufacturing Program 2007 Milestone Achieved – Company Hires Dr. Pedro Huertas as Chief Development Officer Noted Biotech Industry Executive – Experience at Genzyme, StemCells Inc., Novazyme, Amicus Therapeutics Harvard – MIT Trained Physician M.D. from Harvard and MIT Ph.D. from Harvard Univer
Slide 50: GMP Manufacturing Program: Design of Master and Working hESC Banks
GMP Manufacturing Program Design of Master and Working hESC Banks Unlimited Expansion of Stem Cell Line Master Cell Bank Working Cell Bank Bank of Differentiated Cells Bank of Differentiated Cells Bank of Differentiated Cells Single Blastomere
Slide 51: GMP Manufacturing Program: Manufacturing RPE Cells
GMP Manufacturing Program 2007 Milestone Achieved – Company Manufacturing RPE Cells under GMP Compliant Conditions Working Stem Cell Bank Cryopreserved RPE Cell Bank Retinal Pigmented Epithelium
Slide 52: ACT: Corporate Milestones
ACT : Corporate Milestones
Slide 53: 2007 – 2008 Corporate Milestones
2007 – 2008 Corporate Milestones Raise Additional Capital Achieve Listing on National Exchange Commence Phase II Clinical Trial for Myoblast Program File INDs for RPE and Hemangioblast Programs Announce Significant Corporate Partnership Announce Scientific Breakthrough on Solving Histocompatibility
Slide 54: ACTC Value Proposition: Selected Comparable Companies
ACTC Value Proposition Selected Comparable Companies (S mio., except per share data) Osiris OSIR / $14.04 27.4 $384.7 172,590 Phase II/III Stem Cell Therapy NASDAQ Geron Corporation GERN / $7.14 72.9 $520.5 1,660,000 Phase II Cancer / Preclinical hESCs NASDAQ Stem Cells, Inc. STEM / $2.30 80.4 $184.
Slide 55: Thank you for your time
Thank you for your time For more information, visit www.advancedcell.com Advanced Cell Technology is traded on the OTC BB, symbol: ACTC
Advanced Cell Technology — Investor Presentation (July 2007) on 6ix